Bio Pharma Dive
SEPTEMBER 5, 2023
The FDA-approved therapy, called Palforzia, was little used, leading Nestle to abandon a business it had secured in a $2.6 billion deal three years ago.
Pharmaceutical Technology
SEPTEMBER 5, 2023
Nestlé has sold its peanut allergy drug Palforzia to Swiss biopharma Stallergenes Greer harma, concluding a year-long strategic review.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
SEPTEMBER 8, 2023
The company will use its AI technology during a sub-study to analyse the effect of lansoprazole - News - PharmaTimes
Rethinking Clinical Trials
SEPTEMBER 5, 2023
The NIH Pragmatic Trials Collaboratory is launching a special Grand Rounds series to share advances in the design and analysis of pragmatic clinical trials. Join us on the first Friday of each month, October through January, to hear the latest best practices and explore emerging questions with experts from the program’s Biostatistics and Study Design Core.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
SEPTEMBER 5, 2023
The announcement marks progress for Beam after trial delays, and is the first time in the U.S. that a patient has received a base editing treatment.
Pharmaceutical Technology
SEPTEMBER 8, 2023
Eloxx has submitted an IND for a pivotal trial to study its Alport syndrome therapy ELX-02 following a positive Phase II data readout.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Mirror
SEPTEMBER 8, 2023
Niclosamide is an anthelmintic medication that has been used for decades to treat various types of parasitic infections in humans and animals. Niclosamide works by disrupting the energy metabolism of the parasitic worms, specifically by interfering with their ability to generate adenosine triphosphate (ATP), which is essential for their survival. This disruption ultimately leads to the death of the parasites.
Bio Pharma Dive
SEPTEMBER 6, 2023
Jane Grogan, an industry veteran who worked at Genentech for over 15 years, will take over the role starting Oct. 2. She’ll fill a seat that's lacked a permanent replacement since the departure of Al Sandrock.
Pharmaceutical Technology
SEPTEMBER 7, 2023
Veracyte has announced a partnership with Gustave Roussy to support biopharmaceutical companies in expediting the development
Pharma Times
SEPTEMBER 8, 2023
Clinically significant results have emerged from trial evaluating the company’s AMO-02 candidate - News - PharmaTimes
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharma Mirror
SEPTEMBER 6, 2023
by Nataliya Andreychuk, Co-founder and CEO of Viseven Many pharma brands still shy away from marketing directly to patients, depending on conversion through healthcare providers (HCPs). And it is not hard to see why. Compliance with complex laws and regulations, like Direct-to-Consumer Advertising (DTCA) Rules or the Health Insurance Portability and Accountability Act (HIPAA), can be quite daunting.
Bio Pharma Dive
SEPTEMBER 8, 2023
Shape uses machine learning and high throughput screening to identify new AAV capsids in ways the company’s CEO compares to the generative AI tools Midjourney and DALLE-2.
Pharmaceutical Technology
SEPTEMBER 7, 2023
The country returns to the EU’s research programme after a Brexit-related absence and questions surrounding its re-entry prospects.
Pharma Times
SEPTEMBER 7, 2023
The treatment targets extensive stage small cell lung cancer and aims to boost therapeutic impact - News - PharmaTimes
pharmaphorum
SEPTEMBER 7, 2023
Five takeaways from the CAR-TCR cell therapy conference Mike.
Bio Pharma Dive
SEPTEMBER 8, 2023
Worth up to $840 million, the collaboration will give Alexion access to Verge Genomics’ platform, which uses human tissue data to find drug targets for diseases that degrade the nerve system.
Pharmaceutical Technology
SEPTEMBER 6, 2023
The UK MHRA has granted approval for Pfizer and BioNTech’s adapted Covid-19 vaccine (Comirnaty) targeting the Omicron XBB 1.5 subvariant.
Pharma Times
SEPTEMBER 6, 2023
Therapy is used among adult patients with symptomatic obstructive hypertrophic cardiomyopathy - News - PharmaTimes
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Fierce Pharma
SEPTEMBER 6, 2023
IBM disclosed "unauthorized access" to J&J’s Janssen CarePath patient assistance program, which helped over 1 million U.S. patients last year.
Bio Pharma Dive
SEPTEMBER 8, 2023
The PASTEUR Act could be heading for another legislative blow, but advocates say they see a future for the mechanism to fund research into antimicrobial resistance.
Pharmaceutical Technology
SEPTEMBER 6, 2023
The US FDA has requested that AstraZeneca make modifications to the Ultomiris REMS programme to approve a label expansion.
Pharma Times
SEPTEMBER 6, 2023
Technology combines AI-based, ultrasound-guided 3D reconstruction with robotic needle insertion - News - PharmaTimes
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
SEPTEMBER 8, 2023
Combining new and existing immunity: A 3D approach to killing cancer Mike.
Bio Pharma Dive
SEPTEMBER 7, 2023
Fresh off a Series C fundraise, Kriya has acquired the privately held Tramotane Therapeutics and its preclinical candidate for the widely prevalent liver disease.
Pharmaceutical Technology
SEPTEMBER 5, 2023
A new set of European Society of Cardiology (ESC) guidelines was shared at the 2023 ESC conference in Amsterdam, Netherlands.
Pharma Times
SEPTEMBER 5, 2023
Candidate ESO-101 will treat participating patients across five European countries - News - PharmaTimes
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
SEPTEMBER 7, 2023
Inceptive raises $100m, plus other digital financings Phil.
Bio Pharma Dive
SEPTEMBER 6, 2023
The decision is the latest in a series of setbacks for the Actelion spinout and ends a lucrative partnership that began in 2017.
Pharmaceutical Technology
SEPTEMBER 4, 2023
iNtRON's contract is part of the US Army’s DEVCOM strategy to develop drugs to treat antibiotic-resistant UTIs.
Pharma Times
SEPTEMBER 4, 2023
The therapy has been developed for the treatment of migraine among adults - News - PharmaTimes
Expert insights. Personalized for you.
328 
Let's personalize your content